A Phase 2a Study of Safety, Tolerability, and Efficacy of Drug-Delivering Contact Lens LL-BMT1 in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension
Latest Information Update: 09 Jun 2022
At a glance
- Drugs Bimatoprost (Primary)
- Indications Ocular hypertension; Open-angle glaucoma
- Focus Adverse reactions; First in man
- Acronyms SIGHT-1
- Sponsors MediPrint Ophthalmics
- 15 Mar 2022 According to MediPrint Ophthalmics media release, poster highlighting the results from this study will be presented at the American Glaucoma Society (AGS) annual meeting in March 2022.
- 19 Jan 2022 According to MediPrint Ophthalmics media release, data of this study has been presented at the upcoming Global Specialty Lens Symposium (GSLS).
- 08 Jun 2021 According to MediPrint Ophthalmics media release, Dan Myers, the companys CEO attended SECO to discuss the data from this trial and the Companys direction with leading eye care professionals